1.77 USD
↗ 0.05 (3.21%)AT CLOSE (03:59 PM EDT)
TransCode Therapeutics, Inc. Common Stock
RNAZNASDAQ • USD
1.75
↘ 0.02 (1.36%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
1.75
↘ 0.02 (1.36%)
Market: CLOSED
Shares of TransCode Therapeutics, Inc. Common Stock (RNAZ) are trading at $1.77. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (167.1%) and a bearish Death Cross on the long-term moving averages.
Technical & fundamental data as of Oct 23, 2026.
Open?$1.65
High?$1.84
Low?$1.65
Prev. Close?$1.72
Volume?32.7K
Avg. Volume?46.9K
VWAP?$1.78
Rel. Volume?0.70x
Bid / Ask
Bid?$1.67 × 100
Ask?$1.83 × 300
Spread?$0.16
Midpoint?$1.75
Valuation & Ratios
Market Cap?30.0M
Shares Out?N/A
Float?832.3K
Float %?78.6%
P/E Ratio?N/A
P/B Ratio?-1.08
EPS?-$2.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Themes
Employees
12
Market Cap
30.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-07-09
Address
6 LIBERTY SQUARE
BOSTON, MA 02109
Phone: 857-301-6857
BOSTON, MA 02109
Phone: 857-301-6857
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?23
Short Sent.?71
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.66Distress
Confidence?47%Low
Short InterestElevated
Short % of Float?6.26%Elevated
Short Interest?52.1K
Days to Cover?1.0
Free Float832.3K
Avg Daily Volume68.4K
Settlement Date2026-09-30
Financial Health
Current Ratio?1.97Adequate
Quick Ratio?1.97Adequate
Cash Ratio?1.55Strong
Debt/Equity?-0.02Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-1.08CHEAP▾
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?167.1%STRONG▾
Peers50
S&P97
ROA?-30.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-22611971
Enterprise Value?$22.2M
Fundamentals ratios updated end of day